ProfileGDS5678 / 1459347_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 45% 45% 45% 45% 43% 44% 45% 44% 45% 45% 46% 44% 45% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0733644
GSM967853U87-EV human glioblastoma xenograft - Control 23.0521145
GSM967854U87-EV human glioblastoma xenograft - Control 33.0496745
GSM967855U87-EV human glioblastoma xenograft - Control 42.9857845
GSM967856U87-EV human glioblastoma xenograft - Control 53.0142845
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0773943
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0890244
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0351445
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9972344
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0343545
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0340845
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0343246
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0437844
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0428745